Chemical crosslinking and mass spectrometric identification of interaction sites within soluble aggregate of protein therapeutics

Journal of Pharmaceutical and Biomedical Analysis

Volumn 73, Issue , 2013, Pages 99-102

  Zhao, Alan ^a   Hao, Gang ^b   Gu, Jane ^a  

^a Massoverz Technologies   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Aggregation; Antibody; Biotechnology; Crosslinking; Mass spectrometry

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS LINKING; CRYSTAL STRUCTURE; DEUTERIUM HYDROGEN EXCHANGE; HYDROPHILICITY; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; TEMPERATURE STRESS;

ANIMALS; BINDING SITES; CHO CELLS; CHROMATOGRAPHY, GEL; CRICETINAE; CRICETULUS; CROSS-LINKING REAGENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOLOGIC FACTORS; MASS SPECTROMETRY; PEPTIDE MAPPING; PROTEIN MULTIMERIZATION; SOLUBILITY;

EID: 84869505109     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.05.006     Document Type: Article

References (20)

1. Morris A.M., Watzky M.A., Finke R.G. Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim. Biophys. Acta 2009, 1794:375-397.
2. Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta 2004, 1739:5-25.
3. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10(Suppl.):10-17.
4. Lansbury P.T., Lashuel H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006, 443:774-779.
5. Vázquez-Rey M., Lang D.A. Aggregates in monoclonal antibody manufacturing processes. Biotechnol. Bioeng. 2011, 108:1494-1508.
6. Wang W., Nema S., Teagarden D. Protein aggregation-pathways and influencing factors. Int. J. Pharm. 2010, 390:89-99.
7. Rajan R.S., Illing M.E., Bence N.F., Kopito R.R. Specificity in intracellular protein aggregation and inclusion body formation. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13060-13065.
8. Wetzel R. For protein misassembly, it's the I decade. Cell 1996, 86:699-702.
9. Speed M.A., Wang D.I., King J. Specific aggregation of partially folded polypeptide chains: the molecular basis of inclusion body composition. Nat. Biotechnol. 1996, 14:1283-1287.
10. Auer S., Dobson C.M., Vendruscolo M., Maritan A. Self-templated nucleation in peptide and protein aggregation. Phys. Rev. Lett. 2008, 101:258101-258105.
11. Serio T.R., Cashikar A.G., Kowal A.S., Sawicki G.J., Moslehi J.J., Serpell L., Arnsdorf M.F., Lindquist S.L. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 2000, 289:1317-1321.
12. Yao Z.P., Tito P., Robinson C.V. Site-specific hydrogen exchange of proteins: insights into the structures of amyloidogenic intermediates. Methods Enzymol. 2005, 402:389-402.
13. Ashcroft A.E. Mass spectrometry and the amyloid problem-how far can we go in the gas phase?. J. Am. Soc. Mass Spectrom. 2010, 21:1087-1096.
14. Zhang A., Qi W., Singh S.K., Fernandez E.J. A new approach to explore the impact of freeze-thaw cycling on protein structure: hydrogen/deuterium exchange mass spectrometry (HX-MS). Pharm. Res. 2011, 28:1179-1193.
15. Zhang A., Singh S.K., Shirts M.R., Kumar S., Fernandez E.J. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm. Res. 2012, 29:236-250.
16. Sinz A. Chemical cross-linking and mass spectrometry to map three-dimensional protein structures and protein-protein interactions. Mass Spectrom. Rev. 2006, 25:663-682.
17. Petrotchenko E.V., Borchers C.H. Crosslinking combined with mass spectrometry for structural proteomics. Mass Spectrom. Rev. 2010, 29:862-876.
18. Partis M.D., Griffiths D.G., Roberts G.C., Beechey R.B. Cross-linking of protein by co-maleimido alkanoyl N-hydroxysuccinimido esters. J. Protein Chem. 1983, 2:263-277.
19. Paizs B., Suhai S. Fragmentation pathways of protonated peptides. Mass Spectrom. Rev. 2005, 24:508-548.
20. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293:1155-1159.